Program
vorasidenib
Also written as “Vorasidenib”, “AG881” and “AG-881”.
Its studies are mostly in Astrocytoma · Glioma · Leukemia, Myeloid, Acute, led by 5 companies.
Drug pageVorasidenib: every studyMany companies study it; this page follows only the 12 they lead. All 25 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticalsits history only | 50 open or running | phase 1since Jul 6, 2015 | Jul 6, 2015 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.)its history only | 42 open or running | phase 2since Dec 10, 2025 | Nov 14, 2025 | Nov 23, 2026phase 1 · NCT07250633 |
| Servierits history only | 11 open or running | phase 3since Dec 24, 2024 | Dec 24, 2024 | none ahead |
| Servier (Tianjin) Pharmaceuticalits history only | 11 open or running | no phasesince Apr 29, 2025 | Apr 29, 2025 | Apr 2028NCT06969352 |
| Servier Bio-Innovationits history only | 10 open or running | phase 1since Apr 19, 2023 | Apr 19, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 6, 2015First study: phase 1 study in Leukemia, Myeloid, AcuteNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02492737 · 46 enrolled · United States, France
- Jun 9, 2017Named vorasidenibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, AG881, AG-881
- May 21, 2019Phase 1 study in Healthy Male ParticipantsAgios Pharmaceuticals · NCT03960502 · 5 enrolled · United States
- Jul 3, 2019Phase 1 study in Healthy ParticipantsAgios Pharmaceuticals · NCT04015687 · 22 enrolled · United States
- Oct 4, 20192 phase 1 studies in Healthy VolunteersAgios Pharmaceuticals · NCT04128787, NCT04145128
- Apr 19, 2023Servier Bio-Innovation’s first study: phase 1 study in Healthy SubjectsNew to Servier Bio-InnovationServier Bio-Innovation · NCT05843708 · 64 enrolled · United States
- Dec 24, 2024Servier’s first study: phase 3 study in Residual or Recurrent Grade 2 IDH Mutant GliomaNew to ServierServier · NCT06780930 · 57 enrolled · China, Taiwan
- Apr 29, 2025Servier (Tianjin) Pharmaceutical’s first study: no phase study in GliomaNew to Servier (Tianjin) PharmaceuticalServier (Tianjin) Pharmaceutical · NCT06969352 · 62 enrolled · China
- Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)’s first studies: 3 phase 1 studiesNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235774, NCT07235748, NCT07250633
- Dec 10, 2025Phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationPhase 2 reachedInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292 · 10 planned · United States, Australia, Canada
Ahead
- Nov 23, 2026Primary completion: phase 1 study in Severe Hepatic ImpairmentInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07250633
- Apr 2028Primary completion: no phase study in GliomaServier (Tianjin) Pharmaceutical · NCT06969352
- May 2, 2033Primary completion: phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292
TargetBeta
“An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
“IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation · United States, Australia, Canada | 2 | Recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | May 2, 2033 | 10 |
| NCT07250633Severe Hepatic Impairment · United States | 1 | Recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | Nov 23, 2026 | 20 |
| NCT07235774Healthy Adult Female Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Mar 13, 2026 | 28 |
| NCT07235748Healthy Adult Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Dec 23, 2025 | 28 |
| NCT06969352Glioma · China | – | Active, not recruiting | Servier (Tianjin) Pharmaceutical | Apr 2028 | 62 |
| NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma · China, Taiwan | 3 | Active, not recruiting | Servier | May 7, 2026 | 57 |
| NCT05843708Healthy Subjects · United States | 1 | Completed | Servier Bio-Innovation | Jul 28, 2023 | 64 |
| NCT04145128Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Dec 11, 2019 | 32 |
| NCT04128787Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Dec 18, 2019 | 36 |
| NCT04015687Healthy Participants · United States | 1 | Completed | Agios Pharmaceuticals | Oct 9, 2019 | 22 |
| NCT03960502Healthy Male Participants · United States | 1 | Completed | Agios Pharmaceuticals | Sep 7, 2019 | 5 |
| NCT02492737Leukemia, Myeloid, Acute · United States, France | 1 | Completed | Agios Pharmaceuticals | Mar 21, 2018 | 46 |
How it is read
Names in the registry
- “Vorasidenib”, 5 entries
- “AG881”, 2 entries
- “AG-881”, 2 entries
- “Vorasidenib 20mg”, 1 entry
- “Vorasidenib 40 mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Astrocytoma, 1 study
- Glioma, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.